Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Paclitaxel in Triple Negative Breast Cancer: NCT06078384 Clinical Landscape Report 2026
16 October 2026
NCT06078384 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital) in CD19-positive B-cell acute lymphoblastic leukemia: NCT06081478 Clinical Landscape Report 2026
16 October 2026
NCT06081478 clinical landscape for CD19-positive B-cell acute lymphoblastic leukemia: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Pembrolizumab in Triple Negative Breast Cancer: NCT06081244 Clinical Landscape Report 2026
16 October 2026
NCT06081244 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anlotinib Dihydrochloride in Diffuse large B-cell lymphoma refractory: NCT06086197 Clinical Landscape Report 2026
16 October 2026
NCT06086197 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Lurbinectedin in Leiomyosarcoma: NCT06088290 Clinical Landscape Report 2026
16 October 2026
NCT06088290 clinical landscape for Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ifupinostat in Chronic Lymphocytic Leukemia: NCT06082596 Clinical Landscape Report 2026
16 October 2026
NCT06082596 clinical landscape for Chronic Lymphocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
T60c in Solid tumor: NCT06082557 Clinical Landscape Report 2026
16 October 2026
NCT06082557 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IPH-6501 in Mantle-Cell Lymphoma: NCT06088654 Clinical Landscape Report 2026
16 October 2026
NCT06088654 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Brigimadlin in Microsatellite instability-high colorectal cancer: NCT06084689 Clinical Landscape Report 2026
16 October 2026
NCT06084689 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Telisotuzumab adizutecan in Hepatocellular Carcinoma: NCT06084481 Clinical Landscape Report 2026
16 October 2026
NCT06084481 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogeneic CART-NKG2D cells(IdiPAZ) in Advanced Sarcoma: NCT06087341 Clinical Landscape Report 2026
16 October 2026
NCT06087341 clinical landscape for Advanced Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in High grade B-cell lymphoma: NCT06093841 Clinical Landscape Report 2026
16 October 2026
NCT06093841 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.